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Various cytogenetic risk scoring systems may determine prognosis for patients with myelodysplastic syn-
dromes (MDS). We evaluated 4 different risk scoring systems in predicting outcome after allogeneic hemato-
poietic cell transplantation (alloHCT). We classiﬁed 124 patients with MDS using the International Prognostic
Scoring System (IPSS), the revised International Prognostic Scoring System (R-IPSS), Armand’s transplantation-
speciﬁc cytogenetic grouping, and monosomal karyotype (MK) both at the time of diagnosis and at alloHCT.
After adjusting for other important factors, MK at diagnosis (compared with no MK) was associated with poor
3-year disease-free survival (DFS) (27% [95% conﬁdence interval, 12% to 42%] versus 39% [95% conﬁdence in-
terval, 28% to 50%], P ¼ .02) and overall survival (OS) (29% [95% conﬁdence interval, 14% to 44%] versus 47% [95%
conﬁdence interval, 36% to 59%], P ¼ .02). OS but not DFS was affected by MK at alloHCT. MK frequency was
uncommon in low-score R-IPPS and IPSS. Although IPSS and R-IPSS discriminated good/very good groups from
poor/very poor groups, patients with intermediate-risk scores had the worst outcomes and, therefore, these
scores did not show a progressive linear discriminating trend. Cytogenetic risk score change between diagnosis
and alloHCT was uncommon and did not inﬂuence OS. MK cytogenetics in MDS are associated with poor
survival, suggesting the need for alternative or intensiﬁed approaches to their treatment.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Myelodysplastic syndromes (MDS) are heterogeneous
diseases characterized by bone marrow dysplasia, cytope-
nias, and frequent evolution to acute myelogenous leukemia
[1]. Several scoring systems, including the International
Prognostic Scoring System (IPSS), utilize clinical and molec-
ular features, including cytogenetics, to risk stratify patients
[2]. The IPSS was recently revised (R-IPSS) [3]. This revision
maintained bone marrow cytogenetics, marrow blast per-
centage, and cytopenias as the basis of the new system, with
increased stratiﬁcation within these categories. Cytogeneticsedgments on page 871.
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ty for Blood and Marrow Transplantation.has been a major component of all MDS scoring systems. The
R-IPSS deﬁnes 5 cytogenetic subgroups: very good, good,
intermediate, poor, and very poor [3,4], whereas the IPSS
only includes 3 cytogenetic patterns: good, intermediate, and
poor [2]. These scoring systems are used prognostically and
to aid clinical decision-making at initial presentation [5,6].
Higher risk patients are often referred for hematopoietic cell
transplantation (alloHCT), the only potentially curative
treatment for MDS [7-11]. The IPSS and R-IPSS scoring sys-
tems have been shown to predict alloHCT outcomes [12-15].
In addition to these scoring systems, Armand et al. created
and veriﬁed the transplantation-speciﬁc cytogenetic
grouping (TSCG) (standard risk versus adverse risk) that
inﬂuenced the outcomes of alloHCT [16,17]. Other cytoge-
netic groupings recognizing the monosomal karyotype (MK)
are also found to affect overall survival (OS) in MDS patients
[18,19]. The molecular/genetic prognostic landscape remains
C. Ustun et al. / Biol Blood Marrow Transplant 21 (2015) 866e872 867complex in MDS, and it is not clear which prognostic system,
the IPSS, R-IPSS, TSCG, or presence/absence of MK, are the
most clinically relevant in the setting of alloHCT.
To address this question, we compared the ability of these
4 cytogenetic risk stratiﬁcation systems to predict alloHCT
outcomes. Because some MDS patients referred for alloHCT
may have evolution in their cytogenetic risk scores during
pretransplantation therapy, we also evaluated the frequency
of change within each cytogenetic risk score from diagnosis
to alloHCT and whether these changes had any impact on
alloHCT outcomes.PATIENTS AND METHODS
Patient Populations
Through the University of Minnesota blood and marrow transplant
database, we identiﬁed adultMDSpatients (18 years)who underwent their
ﬁrst alloHCTbetween1995 and2012.Onehundred twenty-fourpatientswho
had 10% myeloblasts in the bone marrow at the time of alloHCT (only 9
patients had >10% blasts at alloHCT) and had cytogenetic data at both diag-
nosis and alloHCT were included in the analysis. By excluding patients with
high blast counts at alloHCT, we were able to focus on the effect of the cy-
togenetic scoring systems on outcomes. Our prior analysis showed that high
blast counts had a marked effect on outcome [20], making it difﬁcult to
control for the higher level blasts when evaluating the impact of cytogenetic
scoring, particularly in a cohort of relatively limited number of patients.
Umbilical cord blood (UCB) and volunteer unrelated donors (URDs) were
consideredwhen therewas noHLA-matched sibling available. Depending on
the urgency of transplantation or availability of study protocols, UCB was at
times prioritized over URD. UCB was selected using criteria that we have
previously published [21,22]. UCB graftswerematched at 4 to6 of 6HLA-A, -B
(Ag level) and -DRB1 (allele level) to the recipient, and in patients receiving 2
UCB units, to each other [23,24]. In addition to the HLA matching, stem cell
count in UCB unit was considered in donor selection.Deﬁnitions
MK was deﬁned as the presence of any autosomal monosomy accom-
panied by either 1 additional autosomal monosomy or 1 structural chro-
mosomal abnormality [25]. Cytogenetic classiﬁcations of IPSS, R-IPSS, and
TSCG were described per published studies [2-4] and are summarized in
Supplemental Table 1. Relapse was deﬁned as any recurrence of known
hematologic, morphologic, or cytogenetic markers consistent with disease
before transplantation. Graft-versus-host disease (GVHD) data were
captured prospectively by attending physicians at regular post-HCT intervals
and graded using standard criteria with histopathologic conﬁrmation when
possible [26-29]. Graft source and matching were deﬁned as matched (HLA
8/8 allele matched) versus mismatched (HLA <8/8 matched) bone marrow/
peripheral blood stem cell and matched (HLA 5/6 locus or 6/6 antigen
matched) versus mismatched (HLA <5/6) UCB [23,24]. Conditioning
regimen intensity was deﬁned according to Bacigalupo et al. [30]. Patients
receiving acute myelogenous leukemia (AML)etype induction regimens or
hypomethylating agents were deﬁned as chemotherapy group.Disease-Related Variables
Diagnostic specimens were reviewed by hematopathologists at our
institution and classiﬁed according to the current 2008 World Health Or-
ganization MDS criteria [31]. Therapy-related MDS (t-MDS) was clinically
deﬁned as MDS after exposure to alkylating agents, topoisomerase II in-
hibitors, or radiotherapy within an appropriate timeframe. Clinical variables,
histopathologic data, cytogenetic information, and data on therapy were
obtained via retrospective chart review. Two authors (B.T. and M.D.) inde-
pendently scored all available diagnostic and transplantation cytogenetics;
discrepancies were resolved after consensus review. Standard G-banding
and FISH techniques were used for cytogenetic analysis, with at least 20
metaphase cells analyzed by G-banding and 200 interphase cells analyzed
by FISH.Conditioning Regimens
Conditioning regimens have been previously reported for myeloablative
(MAC)/reduced-intensity conditioning (RIC) related or URD sources andMAC/
RIC UCB donor sources [32-34]. Per institutional protocol, equine antithymo-
cyte globulin (15mg/kg twicedaily3days)wasprovidedtopatientswhohad
not received multi-agent chemotherapy within 3 months of HCT when using
UCB or URD or within 6 months when using a matched related donor.Supportive Care
All patients received supportive care according to institutional guide-
lines, including blood product transfusion, infection prophylaxis (bacterial,
fungal, cytomegalovirus (CMV)/herpes simplex virus, and Pneumocystis jir-
oveci), and GVHD prophylaxis. CMV surveillance was performed weekly
with pre-emptive treatment at the time of positive antigenemia or poly-
merase chain reaction (PCR) testing. For GVHD prophylaxis, the majority of
patients received cyclosporine-based regimens (targeting trough levels of
200 to 400 ng/mL) through dayþ180 with either short-course methotrexate
in MAC regimens or mycophenolate mofetil through day þ30 with RIC or
UCB regimens. Granulocyte-colony stimulating factor was administered to
all patients through neutrophil recovery. Chimerism was determined by
quantitative PCR of informative polymorphic variable number tandem
repeat or short tandem repeat regions in the recipient and donor as
described [23].
Data Collection and Analysis
Patient outcomes after alloHCT were prospectively collected and
recorded in the University of Minnesota bone marrow transplant database.
Treatment protocols were approved by the University of Minnesota
institutional review board and registered at http://clinicaltrials.gov, and all
patients gave informed consent before alloHCT. Factors considered in sta-
tistical analysis included the following: patient age, sex, Karnofsky perfor-
mance status, recipient CMV serostatus, year of transplantation, donor graft
source, conditioning regimen intensity, GVHD prophylactic regimen, MDS
diagnosis according to World Health Organization criteria [35], available
cytogenetics, t-MDS, all 4 cytogenetic risk scoring systems at both diagnosis
and alloHCT, and blast percentage at diagnosis and transplantation.
Statistical Methods
Unadjusted estimates of OS and disease-free survival (DFS) were
calculated by Kaplan-Meier curves [36]. Comparisons were completed with
the simple log rank test. Unadjusted estimates of nonrelapse mortality
(NRM) were analyzed using cumulative incidence treating relapse as a
competing risk. Relapse was similarly analyzed using cumulative incidence
treating mortality as a competing risk. Comparisons were completed with
Gray’s test. Cox regression was used to assess the independent effect of
cytogenetic indices on OS and DFS [37] and Fine and Gray proportional
hazards regression [38] was used to assess the independent effect of indices
on NRM and relapse. Martingale residuals were used to test against non-
proportionality [39] with tests for linear contrasts. After calculation of ﬁnal
regressionmodels, the adjusted OS and DFS curves byMKwere computed as
average estimates of the pooled sample, weighted by the proportions of the
variables in the regression models [40]. Similarly, the adjusted relapse and
NRM curves by MK were estimated based on other signiﬁcant risk factors in
the regression models [41]. SAS 9.3 (SAS Institute, Cary, NC) and R 3.0.2 were
used to perform all statistical analyses.
RESULTS
Patients’ demographic data are shown in Table 1. The
median age was 55 years, and the majority of patients (62%)
received alloHCT after RIC. Twenty-three percent of patients
had t-MDS. Patients were grouped by 4 cytogenetic scoring
systems at the time of diagnosis and at alloHCT (Table 2).
Changes in the cytogenetic score between diagnosis and
alloHCT occurred in 22%, 22%, 14%, and 10% of patients in the
IPSS, R-IPSS, TSCG, and MK cytogenetic scoring systems,
respectively (Table 2).
Patients with or without MK had no signiﬁcant difference
in patient-, disease-, or transplantation-related characteris-
tics except for more t-MDS in MK patients (Table 3). The
frequency of receiving chemotherapy before alloHCT was
also similar in these groups. IPSS cytogenetic risk score
groups had similar characteristics, except the poor-risk
group had a lower blast percentage, more MK, and more
patients with t-MDS (Table 3). MKwas most common in very
poor R-IPSS risk (28 of 29, 96%) followed by poor (6 of 30,
20%), intermediate (1 of 24, 4%), good (1 of 34, 2.9%), and very
good cytogenetic risk groups (0 of 2, 0%). R-IPSS very poor
group had also more patients with t-MDS.
The adjusted Kaplan-Meier estimates of OS and DFS and
cumulative incidence estimates of relapse and NRM by cyto-
genetic scoring system groupings are shown in Table 4.
Table 1
Patient and Transplantation Characteristics
Variable Total Study Group
Year of transplantation 1995-1999 16 (13%)
2000-2006 40 (32%)
2007-2013 68 (55%)
Age of patients, yr <50 41 (33%)
50-60 47 (38%)
>60 36 (29%)
Age, median (range) [IQR] 55 (18-72) [47-62]
Patient gender Male 83 (67%)
KPS <90 25 (21%)
90/100 97 (80%)
Recipient CMV serostatus Negative 57 (46%)
Positive 67 (54%)
Donor type RD/URD match 67 (54%)
RD/URD MM 8 (7%)
UCB 5þ6/6 24 (19%)
UCB 4/6 25 (20%)
Conditioning MAC 47 (38%)
RIC: w/ATG 52 (42%)
RIC: w/o ATG 25 (20%)
GVHD prophylaxis CSA/MMF 75 (61%)
CSA containing 31 (25%)
Other 18 (15%)
Diagnosis MDS-NOS 24 (19%)
MDS-RA 5 (4%)
MDS-RAEB-1 34 (27%)
MDS-RAEB-2 30 (24%)
MDS-RARS 4 (3%)
MDS-RCMD 21 (17%)
RCMD-RS 6 (5%)
Months from diagnosis
to transplantation
Median (range) [IQR] 6 (1-371) [4-13]
t-MDS No 94 (77%)
Yes 28 (23%)
Blast at alloHCT 2% 74 (60%)
2%-<5% 33 (27%)
5%-10% 17 (14%)
IQR indicates interquartile range; KPS, Karnofsky performance status; RD,
related donor;MM,mismatched; ATG, antithymocyte globulin;w/o, without;
CSA, cyclosporine; MMF, mycophenolate mofetil; NOS, not otherwise speci-
ﬁed; RA, refractory anemia; RAEB, refractory anemia with excess blasts;
RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytope-
nias with multilineage dysplasia; RCMD/RS, RCMD with ringed sideroblasts;
URD, unrelated donor; UCB, umbilical cord blood; MAC, myeloablative con-
ditioning; RIC, reduced-intensity conditioning.
Data presented are n (%) unless otherwise speciﬁed.
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risk of patients with MK as well as other confounding factors,
is shown in Table 5. Patients with MK at diagnosis had lower
survival (Figure 1A,B) and higher relapse. Relapse/progres-
sionwas the causeofmortality in52%and20%ofpatientswith
MK and without MK at diagnosis, respectively. In a different
model, when MK at alloHCT was evaluated, it was associatedTable 2
Cytogenetic Risk Scores by Various Systems at Diagnosis and alloHCT
Scoring System Cytogenetics Risk Score At Diagnosis
IPSS Good 35 (29%)
Intermediate 28 (23%)
Poor 58 (48%)
R-IPSS Very good 2 (2%)
Good 34 (28%)
Intermediate 24 (20%)
Poor 32 (26%)
TSCG Favorable 63 (52%)
Adverse 59 (48%)
MK No 83 (70%)
Yes 36 (30%)
Data presented are n (%) unless otherwise indicated.with decreased OS (hazard ratio, 1.9; 95% conﬁdence interval,
1.1 to 3.3; P ¼ .03) but not with relapse (hazard ratio, 1.7; 95%
conﬁdence interval, .8 to 3.9; P¼ .17). Patients with IPSS good
cytogenetic risk score (either at diagnosis or alloHCT) had the
best DFS, OS, and relapse rates, whereas the intermediate risk
group had the highest relapse rate and the shortest survival.
Similarly, patients with R-IPSS very good/good cytogenetic
risk score (either at diagnosis or alloHCT) had the longest DFS
and OS, whereas the intermediate-risk group had the worst
survival. Neither R-IPSS nor IPSS predicted outcomes in an
expected linear fashion (P> .05) because of poor outcomes in
the intermediate group. Outcomes by TSCG were similar be-
tween the adverse or favorable groups. In the regression an-
alyses that focused on the effect of patients with and without
MK, other risk factors for poor OS and higher relapse were
mismatched related donor/URD and RIC without antithymo-
cyte globulin in multivariate regression analysis, respectively
(Table 5). UCB transplantation had no signiﬁcant effect on
relapse, transplantation-related mortality, DFS, or OS in
multivariable analysis.
Changes in cytogenetic risk score between diagnosis and
alloHCT appeared to have no impact on NRM or OS, regard-
less of scoring system. All 3 patients progressing to unfa-
vorable risk from standard-risk score by TSCG died (2 after
relapse). Prior chemotherapy had no effect on relapse, DFS, or
OS in univariate analysis.DISCUSSION
The importance of MK in predicting MDS prognosis con-
tinues to emerge. Nontransplantation studies have shown
that MK has more a signiﬁcant effect on survival compared
with that found in other classiﬁcation systems for complex
cytogenetics in MDS [18,42,43]. The few recent studies
evaluating the importance of MK in alloHCT have reported
results similar to ours. In a speciﬁc cohort of MDS patients
with chromosome 7 abnormalities, Van Gelder et al., using
the European Group for Blood and Marrow Transplantation
database, showed that MK was more predictive of
progression-free survival and OS after alloHCT than complex
cytogenetics was in 261 MDS or AML patients [19]. In fact,
MK and marrow blast counts of >5% were the only prog-
nostic factors for DFS in MDS patients receiving alloHCT [44].
Deeg et al. reported that both MK and R-IPSS cytogenetic risk
score were associated with relapse and survival after alloHCT
inMDS patients [15]. In our study, MKwasmore predictive of
alloHCT outcomes in MDS patients after alloHCT compared
with other established scoring systems. Moreover, theAt alloHCT Change in Cytogenetic Score
between Diagnosis and alloHCT
44 (37%) Improved 17 (15%)
26 (22%) No change 91 (78%)
50 (42%) Progression 9 (8%)
1 (1%) Improved 16 (14%)
44 (37%) No change 91 (78%)
24 (20%) Progression 10 (9%)
25 (21%)
71 (59%) Improved 13 (11%)
49 (41%) No change 102 (86%)
Progression 3 (3%)
90 (75%) Improved 9 (8%)
30 (25%) No change 104 (90%)
Progression 3 (3%)
Table 3
Patient Characteristics by Monosomal Karyotype and IPSS at Diagnosis
Variable No MK MK P Value IPSS P Value R-IPSS P Value
Good Intermediate Poor Good/Very Good Intermediate Poor Very Poor
Age of patient <50 26 (31%) 13 (36%) .82 6 (17%) 14 (50%) 20 (35%) .03 6 (17%) 11 (46%) 15 (47%) 8 (28%) .04
50-60 32 (39%) 14 (39%) 13 (37%) 8 (29%) 25 (43%) 13 (36%) 8 (33%) 11 (34%) 14 (48%)
>60 25 (30%) 9 (25%) 16 (46%) 6 (21%) 13 (22%) 17 (47%) 5 (21%) 6 (19%) 7 (24%)
Age, yr Median (range) 55 (19-72) 52 (19-69) .88 58 (27-72) 52 (21-69) 52 (19-72) .11 59 (27-72) 53 (28-69) 51 (19-72) 53 (22-69) .17
Patient Gender Male 55 (66%) 24 (67%) .97 23 (66%) 17 (61%) 40 (69%) .75 23 (64%) 16 (67%) 23 (72%) 18 (62%) .86
KPS <90 19 (23%) 5 (14%) .29 6 (17%) 7 (25%) 11 (19%) .73 7 (19%) 6 (25%) 7 (22%) 4 (14%) .80
90/100 64 (77%) 30 (83%) 29 (83%) 21 (75%) 46 (79%) 29 (81%) 18 (75%) 25 (78%) 24 (86%)
Recipient CMV Positive 46 (55%) 19 (53%) 19 (54%) 18 (64%) 28 (48%) .38 20 (56%) 16 (67%) 14 (44%) 15 (52%) .39
Donor Type RD/URD Match 42 (51%) 23 (64%) .44 17 (49%) 14 (50%) 35 (60%) .19 18 (50%) 12 (50%) 16 (50%) 20 (69%) .22
RD/URD MM 6 (7%) 2 (6%) 2 (6%) 4 (14%) 2 (3%) 2 (6%) 4 (17%) 1 (3%) 1 (3%)
UCB 5þ6/6 19 (23%) 4 (11%) 11 (31%) 3 (11%) 10 (17%) 11 (31%) 3 (13%) 6 (19%) 4 (14%)
UCB 4/6 16 (19%) 7 (19%) 5 (14%) 7 (25%) 11 (19%) 5 (14%) 5 (21%) 9 (28%) 4 (14%)
Conditioning MA 32 (39%) 13 (36%) .97 11 (31%) 11 (39%) 24 (41%) .78 11 (31%) 8 (33%) 16 (50%) 11 (38%) .61
RIC: w/ATG 35 (42%) 16 (44%) 17 (49%) 10 (36%) 24 (41%) 18 (50%) 9 (38%) 11 (34%) 13 (45%)
RIC: w/o ATG 16 (19%) 7 (19%) 7 (20%) 7 (25%) 10 (17%) 7 (19%) 7 (29%) 5 (16%) 5 (17%)
GVHD prophylaxis CSA/MMF 52 (63%) 21 (58%) .57 23 (66%) 18 (64%) 32 (55%) .77 24 (67%) 17 (71%) 17 (53%) 15 (52%) .49
CSA containing 21 (25%) 8 (22%) 8 (23%) 7 (25%) 15 (26%) 8 (22%) 4 (17%) 11 (34%) 7 (24%)
Other 10 (12%) 7 (19%) 4 (11%) 3 (11%) 11 (19%) 4 (11%) 3 (13%) 4 (13%) 7 (24%)
Diagnosis MDS-NOS 12 (15%) 10 (28%) .30 6 (17%) 5 (18%) 13 (22%) .04 6 (17%) 5 (21%) 13 (21%) 5 (17%) .05
MDS-RA 5 (6%) 0 1 (3%) 2 (7%) 2 (3%) 1 (3%) 3 (13%) 1 (3%) 0
MDS-RAEB-1 21 (25%) 11 (31%) 7 (20%) 6 (21%) 19 (33%) 18 (50%) 4 (17%) 2 (6%) 6 (21%)
MDS-RAEB-2 25 (30%) 5 (14%) 18 (51%) 5 (18%) 7 (12%) 2 (6%) 0 1 (3%) 1 (3%)
MDS-RARS 3 (4%) 1 (3%) 1 (3%) 1 (4%) 2 (3%) 1 (3%) 5 (21%) 7 (22%) 8 (28%)
MDS-RCMD 13 (16%) 8 (22%) 1 (3%) 7 (25%) 13 (22%) 1 (3%) 2 (8%) 1 (3%) 1 (3%)
RCMD-RS 4 (5%) 1 (3%) 1 (3%) 2 (7%) 2 (3%) 7 (19%) 5 (21%) 12 (38%) 8 (28%)
T-MDS Yes 13 (16%) 13 (36%) .01 16 (46%) 5 (18%) 6 (10%) <.01 1 (3%) 4 (17%) 13 (41%) 19 (68%) <.01
Blast at alloHCT 2% 46 (55%) 27 (75%) .07 21 (60%) 15 (54%) 38 (66%) .53 22 (61%) 13 (54%) 18 (56%) 21 (72%) .61
>2%-<5% 25 (30%) 4 (11%) 11 (31%) 8 (29%) 11 (19%) 11 (31%) 7 (29%) 8 (25%) 4 (14%)
5%-10% 12 (15%) 5 (14%) 3 (9%) 5 (18%) 9 (16%) 3 (8%) 4 (17%) 6 (19%) 4 (14%)
Chemotherapy No 43 (52%) 16 (44%) .46 34 (97%) 23 (85%) 35 (61%) <.01 35 (97%) 23 (96%) 24 (80%) 1 (3%) <.01
Yes 40 (48%) 20 (56%) 1 (3%) 4 (15%) 22 (39%) 1 (3%) 1 (4%) 6 (20%) 28 (97%)
MK No 34 (97%) 27 (96%) 22 (39%) <.01 6.7 (1-372) 7.4 (2-63) 5.4 (2-73) 5.2 (2-38) .06
Yes 1 (3%) 1 (4%) 34 (61%) 1 (3%) 4 (17%) 13 (41%) 19 (68%) <.01
Months to alloHCT Median (range) 6.7 (1-372) 5.3 (2-39) .14 6.3 (1-77) 10.4 (2-81) 5.3 (2-372) .58 22 (61%) 13 (54%) 18 (56%) 21 (72%) .61
TX indicates treatment.
Data presented are n (%) unless otherwise speciﬁed.
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Table 4
The Effects of Cytogenetic Scoring System Groupings on alloHCT Outcomes adjusted for Donor Type, Conditioning, and Baseline Karnofsky
Time Cytogenetic
Scoring
Systems
Cytogenetic
Risk Score
NRM at 3 Years P Value Relapse at
3 Years
P Value DFS at 3 Years P Value OS at 3 Years P Value
At diagnosis IPSS Good 22% (8%-36%) .01 21% (8%-34%) .28 59% (43%-73%) <.01 67% (51%-83%) <.01
Intermediate 55% (45%-65%) 35% (17%-53%) 11% (1%-23%) 16% (4%-30%)
Poor 42% (28%-56%) 26% (15%-37%) 32% (20%-44%) 37% (24%-50%)
R-IPSS Very good/good 21% (7%-35%) <.01 23% (9%-37%) .02 57% (41%-73%) <.01 66% (50%-82%) <.01
Intermediate 59% (38%-80%) 36% (17%-55%) 8% (1%-19%) 19% (3%-35%)
Poor 47% (29%-65%) 10% (1%-21%) 41% (24%-58%) 44% (26%-62%)
Very poor 35% (16%-54%) 39% (22%-56%) 24% (7%-41%) 27% (11%-44%)
TSCG Standard 36% (24%-48%) .29 28% (17%-39%) .98 37% (25%-49%) .36 44% (31%-57%) .28
Adverse 44% (31%-57%) 26% (15%-37%) 31% (19%-43%) 36% (24%-48%)
MK No 40% (29%-51%) .96 23% (14%-32%) .02 39% (28%-50%) .01 47% (36%-59%) .02
Yes 35% (19%-51%) 38% (23%-43%) 27% (12%-42%) 29% (14%-44%)
At alloHCT IPSS Good 27% (13%-41%) .19 27% (14-40%) .86 47% (32-62%) .09 57% (42-72%) <.01
Intermediate 56% (36-76%) 29% (12%-46%) 19% (4%-34%) 22% (6%-38%)
Poor 43% (29%-57%) 25% (13%-37%) 32% (19%-45%) 36% (22%-50%)
R-IPSS Very good/good 27% (13%-31%) .23 29% (16%-52%) .84 45% (30%-60%) .02 56% (41%-71%) <.01
Intermediate 59% (39%-79%) 27% (10%-44%) 18% (3%-33%) 24% (6%-42%)
Poor 37% (17%-57%) 18% (2%-34%) 44% (23%-65%) 49% (29%-69%)
Very poor 46% (26%-66%) 31% (14%-47%) 24% (6%-42%) 23% (6%-40%)
TSCG Standard 40% (28%-52%) .51 27% (17%-37%) .73 36% (24%-48%) .27 42% (31%-54%) .34
Adverse 41% (27%-54%) 28% (16%-40%) 32% (19%-45%) 38% (24%-52%)
MK No 41% (31%-51%) .85 25% (16%-34%) .17 36% (26%-46%) .10 43% (33%-53%) .08
Yes 39% (21%-60%) 34% (18%-50%) 28% (12%-44%) 31% (14%-48%)
Data presented are incidence of outcome of interest (95% conﬁdence interval.)
C. Ustun et al. / Biol Blood Marrow Transplant 21 (2015) 866e872870presence of MK, both at diagnosis and at alloHCT, was pre-
dictive of survival after alloHCT; to our knowledge, ours is the
ﬁrst study to evaluate this. We also showed that MK fre-
quency was correlated with R-IPSS cytogenetic risk score;
the highest frequency of MK was found in the R-IPSS very
poor cytogenetic risk group and was progressively less
frequent in the more favorable risk groups, similar to the
ﬁndings of Deeg et al. [15]. Although some studies indicate
that a complex karyotype is more prognostic than MK in the
non-alloHCT MDS setting [45,46], we could not evaluate this
because of the strong correlation between MK and R-IPSS
very poor cytogenetic risk group (>3 cytogenetic
abnormalities).
The IPSS and R-IPSS have been shown in previous studies
to be associated with outcomes of alloHCT [12,15,47,48]. OurTable 5
Multiple Regression Analyses through Three Years for NRM, Relapse, DFS, and OS
Factors* N RR of
NRM (95% CI)
P Value RR of Relapse
(95% CI)
MK at diagnosis
No 83 1.0 1.0
Yes 36 1.0 (.5-2.0) .96 2.4 (1.1-5.3)
Donor type
Matched RD/URD 67 1.0 1.0
MM RD/URD 8 5.9 (2.4-14.5) <.01 No events
5þ6/6 UCB 24 .9 (.4-2.4) .91 .5 (.2-1.5)
4/6 UCB 25 1.2 (.5-2.6) .88 .9 (.4-2.3)
Conditioning
MAC 47 1.0 1.0
RIC: w/ATG 52 1.1 (.5-2.4) .87 2.1 (.8-5.5)
RIC: w/o ATG 25 1.3 (.6-2.9) .48 3.4 (1.3-9.3)
KPS
90-100* 97 1.0 1.0
<90 25 1.1 (.6-2.2) .73 1.5 (.6-4.0)
Grade II-IV aGVHD (time dependent)
No 76 1.0 1.0
Yes 48 1.0 (.5-2.0) .99 .7 (.3-1.5)
RR, relative risk; 95% CI, 95% conﬁdence interval.
* Tested for MK at diagnosis (no versus yes), age (<50 versus 50 to 60 versus 60þ
gender (male versus female), KPS (<90 versus 90/100), CMV serostatus (positive ve
UCB versus 4/6 UCB), conditioning (myeloablative versus RIC with ATG versus RIC
cyclosporine/other versus other), diagnosis (RA/RARS versus RAEB versus RCMD ve
(2% versus 3% to 4% versus 5% to 10%).study was in line with other studies in that it highlights the
predictive potential of IPSS and R-IPSS, primarily in the good-
risk cytogenetic groups, which had the best expected out-
comes after alloHCT. In addition, we noted aworsening trend
for relapse, DFS, and OS from the good/very gooderisk group
toward the poor/very poorerisk group. However, the
intermediate-risk groups classiﬁed by both IPSS and R-IPSS
had unexpectedly poor outcomes (the highest NRM and
relapse yielding the lowest DFS and OS) in our cohort. When
we compared factors among risk scoring groups in IPSS and
R-IPSS scoring system, such as blast percentage or inferior
Karnofsky performance status, there was no signiﬁcant dif-
ference to explain the poor outcome in the intermediate
groups. In our study, we found that the TSCG had no utility in
predicting alloHCT outcomes [16,17]. The difference betweenP Value RR of Relapse/
Death (95% CI)
P Value RR of Death
(95% CI)
P Value
1.0 1.0
.02 2.0 (1.2-3.4) .01 1.9 (1.1-3.3) .02
1.0 1.0
<.01 2.8 (1.2-6.4) .02 3.7 (1.6-8.8) <.01
.26 .7 (.4-1.5) .40 .7 (.3-1.6) .45
.85 1.0 (.5-1.8) .96 1.2 (.6-2.3) .58
1.0 1.0
.13 1.6 (.9-2.8) .14 1.5 (.8-2.8) .20
.02 2.3 (1.2-4.4) .01 2.2 (1.1-4.2) .02
1.0 1.0
.43 1.7 (1.0-3.0) .06 1.6 (.9-3.0) .10
1.0 1.0
.33 .7 (.4-1.1) .12 .9 (.5-1.6) .78
), year of alloHCT (1995 to 1999 versus 2000 to 2006 versus 2007 to 2013),
rsus negative), donor type (RD/URDmatch versus RD/URDMM versus 5þ6/6
w/o ATG), GVHD prophylaxis (cyclosporine/mycophenolate mofetil versus
rsus unknown), treatment-related MDS (no versus yes) and blasts at alloHCT
Adjusted Overall Survival
0.0
0.2
0.4
0.6
0.8
1.0
0 6 12 18 24 30 36
Months
Cu
m
ul
a
ve
 P
ro
po
r
on
No MK
MK
P = .02
Adjusted Disease-Free Survival
Months
Cu
m
ul
a
ve
 P
ro
po
r
on
No MK
MK
P = .01
0.0
0.2
0.4
0.6
0.8
1.0
0 6 12 18 24 30 36
A
B
Figure 1. OS (A) and DFS (B) at 3 years by MK.
C. Ustun et al. / Biol Blood Marrow Transplant 21 (2015) 866e872 871our study and other large studies [15,48] may be due in part
to the limited number of patients in our study. Moreover, our
study cohort had the largest UCB transplantation. UCB
transplantation has been used in MDS patients [20,49,50].
Although there is no study directly comparing UCB with
other graft sources for MDS, comparable results were shown
in acute myelogenous leukemia [51,52]. In our study, UCB
transplantation frequency was similar within the cytogenetic
scoring systems, and was not found to be associated with
relapse, transplantation-related mortality, DFS, or OS.
Changes between diagnosis and alloHCT in cytogenetics
risk score group in each scoring system occurred were un-
common. These cytogenetic changes had little inﬂuence on
outcomes of alloHCT. In general, the value of cytogenetic risk
scoring in alloHCT outcomes was similar between classiﬁca-
tion at diagnosis and at alloHCT. Although this was not 1 of the
primary objectives of our retrospective analysis and the pa-
tient cohort was relatively small, this might indicate that
outcomes of alloHCT were not affected signiﬁcantly by ther-
apy between diagnosis and alloHCT. The effect of therapy in
MDS before alloHCT is still controversial, mainly because all
reported results are from retrospective studies [7,48,53-57]. In
a large single-center study, Oran et al. showed that therapy
before alloHCTand disease status at alloHCTwere not found to
be prognostic for any disease outcome [44]. OS at 5 years was
57% for patients who underwent alloHCT as a primary treat-
ment for refractory anemia with excess blasts or secondary
AML and 54% for those who underwent alloHCT in remission
after induction chemotherapy (P ¼ .81) [53]. In that study,
achieving complete remission (CR) before standard alloHCT
was not associated with a better prognosis after trans-
plantation; however, disease status had a signiﬁcant impact in
patients who progressed to AML. In contrast, other studies
have indicated status is important for alloHCT outcomes[47,57-59]. In our prior study, we highlighted the importance
of blast percentage at the time of transplantation in MDS
patients [20]. Consequently, to focus this analysis on the
impact of cytogenetic risk group instead of confounding
characteristic of high blast burden, we excluded a limited
number of patients who had >10% marrow blasts at alloHCT
in this cohort. A recent European Group for Blood andMarrow
Transplantation study showed that in patients with high-risk
cytogenetic score by IPSS, the relapse rate at 5 years wasmuch
higher if they were in CR (70%) versus not in CR (38%). How-
ever, relapse was lower in patients with low-risk cytogenetic
score in CR (38% versus 18%) [48]. These ﬁndings in our and
other studies may suggest that cytogenetic risk group may be
more important than CR status in MDSdCR is a difﬁcult
endpoint to measure in MDS, regardless.
In conclusion, this study evaluates the ability of 4 different
cytogenetic scoring systems used at diagnosis and alloHCT to
predict outcome.We found thatMK, particularly at diagnosis,
is the cytogenetic risk scoring systemmost predictive of post
alloHCT outcomes. Changes in the cytogenetics risk score
between diagnosis and alloHCT occur only rarely and have
limited effects on outcomes of alloHCT. Therefore, cytogenetic
risk scoring at diagnosis or at alloHCT seemed to have similar
power of prediction of alloHCT outcomes.ACKNOWLEDGMENTS
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